Praxis Precision Medicines (PRAX) was upgraded by Truist Financial Corporation to "strong-buy".
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit [Yahoo! Finance]
Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization? [Yahoo! Finance]
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter [Yahoo! Finance]
Is Praxis Precision Medicines (PRAX) Still Attractive After Its Big Share Price Run? [Yahoo! Finance]